Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Roberta Modica, Alessia Liccardi, Roberto Minotta, Giuseppe Cannavale, Elio Benevento & Annamaria Colao. (2022) Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. Expert Review of Endocrinology & Metabolism 17:5, pages 389-403.
Read now
Read now
Tetsuhide Ito & Robert T Jensen. (2021) Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes. Expert Opinion on Pharmacotherapy 22:6, pages 685-693.
Read now
Read now
Massimo Falconi, Nicola Fazio, Diego Ferone & Annibale Versari. (2020) Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey. Expert Opinion on Pharmacotherapy 21:18, pages 2317-2324.
Read now
Read now
Lingaku Lee, Tetsuhide Ito & Robert T Jensen. (2019) Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies. Expert Review of Anticancer Therapy 19:12, pages 1029-1050.
Read now
Read now
Articles from other publishers (32)
Qing-Wei Cheng, Hong-Li Shen, Zhi-Hui Dong, Qian-Qian Zhang, Ya-Fen Wang, Jin Yan, Yu-Sheng Wang & Ning-Gang Zhang. (2023)
Pneumocystis jirovecii
diagnosed by next-generation sequencing of bronchoscopic alveolar lavage fluid: A case report and review of literature
. World Journal of Clinical Cases 11:4, pages 866-873.
Crossref
Crossref
Fuqiang Zhao, Liling Huang, Zhijie Wang, Fangze Wei, Tixian Xiao & Qian Liu. (2023) Epidemiological trends and novel prognostic evaluation approaches of patients with stage II-IV colorectal neuroendocrine neoplasms: A population-based study with external validation. Frontiers in Endocrinology 14.
Crossref
Crossref
Lorena Hernandez-Rienda, Maria Isabel del Olmo-García & Juan Francisco Merino-Torres. (2022) Impact of Diabetes Mellitus in Patients with Pancreatic Neuro-Endocrine Tumors: Causes, Consequences, and Future Perspectives. Metabolites 12:11, pages 1103.
Crossref
Crossref
Maria Ingenerf, Sophia Kiesl, Michael Winkelmann, Christoph J. Auernhammer, Johannes Rübenthaler, Freba Grawe, Matthias P. Fabritius, Jens Ricke & Christine Schmid-Tannwald. (2022) Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters. Biomedicines 10:10, pages 2618.
Crossref
Crossref
Chirayu Mohindroo, Florencia McAllister & Ana De Jesus-Acosta. (2022) Genetics of Pancreatic Neuroendocrine Tumors. Hematology/Oncology Clinics of North America 36:5, pages 1033-1051.
Crossref
Crossref
Damiano Caruso, Michela Polici, Maria Rinzivillo, Marta Zerunian, Ilaria Nacci, Matteo Marasco, Ludovica Magi, Mariarita Tarallo, Simona Gargiulo, Elsa Iannicelli, Bruno Annibale, Andrea Laghi & Francesco Panzuto. (2022) CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors. La radiologia medica 127:7, pages 691-701.
Crossref
Crossref
Nicoletta Ranallo, Andrea Prochoswski Iamurri, Flavia Foca, Chiara Liverani, Alessandro De Vita, Laura Mercatali, Chiara Calabrese, Chiara Spadazzi, Carlo Fabbri, Davide Cavaliere, Riccardo Galassi, Stefano Severi, Maddalena Sansovini, Andreas Tartaglia, Federica Pieri, Laura Crudi, David Bianchini, Domenico Barone, Giovanni Martinelli, Giovanni Luca Frassineti, Toni Ibrahim, Luana Calabrò, Rossana Berardi & Alberto Bongiovanni. (2022) Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis. Cancers 14:13, pages 3231.
Crossref
Crossref
Kseniya Glinkina, Arwin Groenewoud, Amina F. A. S. Teunisse, B. Ewa Snaar-Jagalska & Aart G. Jochemsen. (2022) Novel Treatments of Uveal Melanoma Identified with a Synthetic Lethal CRISPR/Cas9 Screen. Cancers 14:13, pages 3186.
Crossref
Crossref
Madlen Kaldirim, Alexander Lang, Susanne Pfeiler, Pia Fiegenbaum, Malte Kelm, Florian Bönner & Norbert Gerdes. (2022) Modulation of mTOR Signaling in Cardiovascular Disease to Target Acute and Chronic Inflammation. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Yuan-Liang Li, Zi-Xuan Cheng, Fu-Huan Yu, Chao Tian & Huang-Ying Tan. (2022) Advances in medical treatment for pancreatic neuroendocrine neoplasms. World Journal of Gastroenterology 28:20, pages 2163-2175.
Crossref
Crossref
Lingaku Lee, Irene Ramos-Alvarez & Robert T. Jensen. (2022) Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers 14:5, pages 1250.
Crossref
Crossref
Rong Ma & Loganathan Karthik. 2022. Actinobacteria. Actinobacteria
265
276
.
Sudip Mukherjee & Vijay Sagar MadamsettySudip Mukherjee & Vijay Sagar Madamsetty. 2022. Nanoparticles in Angiogenesis and Cancer. Nanoparticles in Angiogenesis and Cancer
11
19
.
Brendon Herring, Samuel Jang, Jason Whitt, Kayla Goliwas, Zviadi Aburjania, Vikas Dudeja, Bin Ren, Joel Berry, James Bibb, Andra Frost, Herbert Chen, John Bart Rose & Renata Jaskula-Sztul. (2021) Ex Vivo Modeling of Human Neuroendocrine Tumors in Tissue Surrogates. Frontiers in Endocrinology 12.
Crossref
Crossref
Xiang-yi Huang, Qing-peng Hu, Hong-yun Shi, Ya-yu Zheng, Rong-rong Hu & Qian Guo. (2021) Everolimus inhibits PI3K/Akt/mTOR and NF-kB/IL-6 signaling and protects seizure-induced brain injury in rats. Journal of Chemical Neuroanatomy 114, pages 101960.
Crossref
Crossref
Jingwen Xue, Jianan Bai, Qin Long, Yaling Wei, Jialing Pan, Xiaolin Li & Qiyun Tang. (2021) TCF-3-mediated transcription of lncRNA HNF1A-AS1 targeting oncostatin M expression inhibits epithelial-mesenchymal transition via TGFβ signaling in gastroenteropancreatic neuroendocrine neoplasms. Aging 13:10, pages 14065-14077.
Crossref
Crossref
Özlem Şen, Melis Emanet & Gianni Ciofani. (2021) Nanotechnology‐Based Strategies to Evaluate and Counteract Cancer Metastasis and Neoangiogenesis. Advanced Healthcare Materials 10:10, pages 2002163.
Crossref
Crossref
Sarah Christine Elisabeth Wright, Natali Vasilevski, Violeta Serra, Jordi Rodon & Pieter Johan Adam Eichhorn. (2021) Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity. Cancers 13:7, pages 1538.
Crossref
Crossref
Jianming Xu. (2021) Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs). Therapeutic Advances in Medical Oncology 13, pages 175883592110426.
Crossref
Crossref
Jonathan Koea, Julie Hallett, Calvin Law, Janice Pasieka, Jonathan Koea & Win Meyer-Rochow. (2020) Management of Locally Advanced and Unresectable Small Bowel Neuroendocrine Tumours. World Journal of Surgery 45:1, pages 219-224.
Crossref
Crossref
Sara Zanini, Serena Renzi, Francesco Giovinazzo & Giovanna Bermano. (2020) mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs). Frontiers in Endocrinology 11.
Crossref
Crossref
Christoph Wetz, Julian Rogasch, Philipp Genseke, Imke Schatka, Christian Furth, Michael Kreissl, Henning Jann, Marino Venerito & Holger Amthauer. (2020) Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment?. Diagnostics 10:9, pages 732.
Crossref
Crossref
Anubhab Mukherjee, Vijay Sagar Madamsetty, Manash K. Paul & Sudip Mukherjee. (2020) Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer. International Journal of Molecular Sciences 21:2, pages 455.
Crossref
Crossref
Brendon Herring, Jason Whitt, Tolulope Aweda, Jianfa Ou, Rachael Guenter, Suzanne Lapi, Joel Berry, Herbert Chen, Xiaoguang Liu, J. Bart Rose & Renata Jaskula-Sztul. (2020) A growth model of neuroendocrine tumor surrogates and the efficacy of a novel somatostatin-receptor–guided antibody-drug conjugate: Perspectives on clinical response?. Surgery 167:1, pages 197-203.
Crossref
Crossref
Matthew S. Jorgensen, Lisa M. Velez-Velez, Horacio Asbun & Gerardo Colon-Otero. (2019) Everolimus Is Effective Against Metastatic Solid Pseudopapillary Neoplasm of the Pancreas: A Case Report and Literature Review. JCO Precision Oncology:3, pages 1-6.
Crossref
Crossref
Antongiulio Faggiano, Silvana Di Maio, Carmela Mocerino, Margaret Ottaviano, Chiara De Divitiis, Valentina Guarnotta, Pasquale Dolce, Roberta Modica, Ivana Puliafito, Lucia Tozzi, Antonella Di Sarno, Silvana Leo, Ferdinando Riccardi, Giovannella Palmieri, Salvatore Tafuto, Antonella Bianco, Giuseppe Badalamenti & Annamaria Colao. (2019) Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. Endocrine 66:2, pages 417-424.
Crossref
Crossref
Lingaku Lee, Irene Ramos-Alvarez, Tetsuhide Ito & Robert T. Jensen. (2019) Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome. International Journal of Molecular Sciences 20:20, pages 5128.
Crossref
Crossref
Katopodis, Chudasama, Wander, Sales, Kumar, Pandhal, Anikin, Chatterjee, Hall & Karteris. (2019) Kinase Inhibitors and Ovarian Cancer. Cancers 11:9, pages 1357.
Crossref
Crossref
Federico Gatto, Federica Barbieri, Marica Arvigo, Stefano Thellung, Jessica Amarù, Manuela Albertelli, Diego Ferone & Tullio Florio. (2019) Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms. International Journal of Molecular Sciences 20:16, pages 3940.
Crossref
Crossref
Giulia Bresciani, Angeliki Ditsiou, Chiara Cilibrasi, Viviana Vella, Federico Rea, Marco Schiavon, Narciso Giorgio Cavallesco, Georgios Giamas, Maria Chiara Zatelli & Teresa Gagliano. (2019) EGF and IGF1 affect sunitinib activity in BP-NEN: new putative targets beyond VEGFR?. Endocrine Connections 8:6, pages 680-690.
Crossref
Crossref
David Romano. (2019) Relevance of neuroendocrine tumours models assessed by kinomic profiling. Annales d'Endocrinologie 80:3, pages 144-148.
Crossref
Crossref
Jiadong Cheng, Lan Hu, Zheng Yang, Caixia Suo, Yueyang Jack Wang, Ping Gao, Chengbin Cui & Linchong Sun. (2019) 2-Oxonanonoidal Antibiotic Actinolactomycin Inhibits Cancer Progression by Suppressing HIF-1α. Cells 8:5, pages 439.
Crossref
Crossref